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Evaluation of Restricted Medications
Administered Within the Inpatient Setting

Alexis Nicholson, PharmD, Janine Barnaby, RPh, BS, BCOP, Arun Mancheril, PharmD, BCPS, Kristin Held Wheatley, PharmD, BCOP
Pharmacy Department, Lehigh Valley Health Network, Allentown PA

Background

• Changes to reimbursement models have shifted
how health systems provide patient care
• Commercial payors are driving health care
services to lower cost sites of care (i.e. nonhospital based infusion centers), including
services such as medication administration.
• To ensure medication administration occurs
within the most cost-effective setting, a list of
restricted medications was developed at Lehigh
Valley Health Network.
Medications were included if high-cost, used
for management of chronic disease states, or
targeted for outpatient administration
Three-step approval process (provider contact,
pharmacy administrator approval, pharmacist
documentation)
List has not been formally reviewed or revised
since 2017
• Goal of this quality improvement project was to
assess the inpatient use of restricted
medications and identify changes that should be
made or opportunities for education to
streamline the approval process while mitigating
effects of changing sites of care and
reimbursement.

Methods

• Retrospective review of electronic medical
records of inpatient administrations of restricted
medications between July 1, 2018 and June 30,
2020 at LVH–Cedar Crest and LVH–Muhlenberg.
• Evaluations performed:
Calculated total number of doses administered
per medication per fiscal year (July 1–June 30)
Stratified usage by drug and patient location
and identified significant trends in prescribing
Quantified documentation for usage approval
and assessed for consistency

Results

Table 1. Evaluation of Doses Administered
by Fiscal Year
Restricted medication
2018-2019
2019-2020
classification
(N=56)* n (%) (N=51)* n (%)
Restricted medication usage
Bendamustine
7 (12.5)
7 (13.7)
Leuprolide
13 (23.2)
4 (7.8)
Tocilizumab
12 (21.4)
1 (2.0)
Vedolizumab
8 (14.3)
14 (27.5)
Patient-supplied medication
7 (12.5)
8 (15.7)
Rationale for inpatient administration
Administration logistics
50 (89.3)
29 (56.9)
Medically necessary
16 (28.6)^
35 (68.6)^
*Administrations by hospital campus (2018-2019: Cedar Crest n=54, Muhlenberg n=2;
2019-2020: Cedar Crest n=39, Muhlenberg n=12)
^Medically necessary doses (2018-2019: 14 initial doses; 2 maintenance doses;
2019-2020: 32 initial doses; 3 maintenance doses)

Restricted Medication Administration by Hospital Service
Figure 1: 2018–2019

Figure 2: 2019–2020
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Documentation for Restricted Medication Use
Figure 3: 2018–2019

Conclusions

•	Administration of patient’s own medications was
faciliated across fiscal years
•	More restricted medications ordered by oncology
department and administered for medical
treatment of acute conditions in 2019-2020 vs
2018-2019
•	Failure to document intervention or
communication with providers regarding
restricted medication administration occurred
more than 1/3 of the time
Documentation disparity varied by hospital
campus
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Figure 4: 2019–2020
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